演題詳細

ポスター / Poster

ポスター 35 (Poster 35) :骨髄腫:症例(レナリドミド)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
和泉 透 (Tohru Izumi):1
1:栃木県立がんセンター 血液内科
 
前へ戻る

lenalidomide + low-dose dexamethasone (Ld) as a primary therapy for patients with multiple myeloma

演題番号 : PS-1-268

武岡 康信 (Yasunobu Takeoka):1、小倉 和人 (Kazuto Ogura):2、山村 亮介 (Ryosuke Yamamura):1、藤谷 洋太朗 (Yotaro Fujitani):1、荒木 拓 (Taku Araki):1、稲葉 晃子 (Akiko Inaba):1、中尾 隆文 (Takafumi Nakao):3、吉田 全宏 (Hiroshi Yoshida):3、金島 広 (Hiroshi Kanashima):3、山根 孝久 (Takahisa Yamane):3、池田 宇次 (Takashi Ikeda):2、太田 健介 (Kensuke Ohta):1

1:Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Japan、2:Division of Hematology & Stem Cell Transplantation, Shizuoka Cancer Center, Japan、3:Department of Hematology, Osaka City General Hospital, Japan

 

[Objective and Method]We retrospectively analyzed the efficacy and safety of lenalidomide (Len) plus low-dose dexamethasone (Ld) as a primary therapy for patients with multiple myeloma (MM) diagnosed between December 2010 and January 2013.
[Results]Twenty two patients with median age of 75 (range 65-87) were evaluable. ISS stage was 2 or worse in 18 patients. The patients had received a median of 6 courses of Ld therapies with an average Len of 15mg/day (on the assumption that Len was taken for 3 weeks in all the courses). Thirteen patients were still on Ld therapy after receiving 9 courses with 15 mg/day of Len, and 9 had discontinued the therapy after receiving 4 courses with 10 mg/day. The cause of therapy discontinuation was progressive diseases in 3 patients and adverse events (AE) in 6. VGPR or better responses were obtained in 45% of whole patients and in 78% of those received 10 or more courses of Ld. The patients who achieved >VGPR and [Discussion]Whereas 78 % of the patients achieved >VGPR with long-term treatment with 15 mg/day of Len, 32% developed severe AE only with 5.5 mg/day. The observations indicate that, for very elderly patients, Len may be started from minimal dose (e.g., 5 mg/day), gradually increase to maximum tolerable dose (preferentially 15 mg/day or more) and continue longer. This partially coincides with the recommendation of the European Myeloma Network (Blood,2011).

前へ戻る